Novartis has signed a licensing deal worth up to $5.7B with Monte Rosa Therapeutics to advance novel protein degradation therapies, underscoring the growing prominence of molecular glue degraders in drug discovery. The collaboration will leverage Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform, designed to systematically identify small molecules that harness the cell’s natural ubiquitin-proteasome system to eliminate disease-causing proteins.
Unlike traditional small-molecule inhibitors, which typically bind to active sites on proteins, molecular glue degraders work by reprogramming cellular machinery to tag target proteins for degradation. This approach enables the selective removal of proteins that may lack conventional binding pockets, offering a way to pursue previously “undruggable” targets in oncology, immunology, and other complex therapeutic areas.
Through the deal, Novartis will gain access to Monte Rosa’s discovery engine and pipeline, aiming to accelerate the development of next-generation therapeutics that expand beyond inhibition into functional protein elimination. In return, Monte Rosa will receive upfront funding, clinical and regulatory milestone payments, and royalties on marketed therapies.
The agreement highlights how protein degradation is emerging as a disruptive modality in the pharmaceutical industry, with potential to transform treatment paradigms for cancers and other intractable diseases.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!